| L-Theanine — Naturally occurring non-protein amino-acid derivative (γ-glutamylethylamide) found primarily in tea leaves (Camellia sinensis). L-Theanine readily crosses the blood-brain barrier and has been studied for effects on relaxation, stress, attention, cognition, sleep quality, neurotransmission, and neuroprotection.
Primary clinical relevance: Human studies support modest effects on relaxation, stress reduction, attention, and selected aspects of sleep and cognitive performance, particularly when combined with caffeine. Effects vary by dose, population, and outcome measured.
Cancer relevance: Primarily preclinical. L-Theanine has demonstrated antiproliferative, pro-apoptotic, antioxidant, immunomodulatory, and chemosensitizing effects in selected experimental cancer models. It has also been investigated for modulation of glutamate transport and for enhancement of the activity or tolerability of some chemotherapeutic agents. Evidence is insufficient to consider it an established anticancer treatment.
Alzheimer’s disease / neurodegeneration relevance: Preclinical evidence suggests potential neuroprotective effects through modulation of glutamatergic signaling, oxidative stress, inflammation, and neuronal survival. Human evidence specifically for Alzheimer’s disease remains limited.
Typical mechanisms: Glutamatergic signaling modulation; GABAergic activity modulation; dopamine and serotonin signaling modulation; stress-response signaling ↓; oxidative stress ↓; neuroinflammation ↓; excitotoxicity ↓. Cancer-related mechanisms are model-dependent and may include proliferation ↓ and apoptosis ↑.
Typical supplemental dose: Common oral supplemental doses are approximately 100–400 mg/day, often given as 100–200 mg per dose.
product classification: Nutraceutical / amino-acid derivative.
Natural Sources of L-Theanine
| Rank |
Product / Source |
L-Theanine (mg/g dry product) |
Typical Serving |
L-Theanine per Serving (mg) |
Notes / Interpretation |
| 1 |
Matcha, premium shade-grown Japanese |
29–45 |
2 g powder |
58–90 |
Among the richest dietary sources. Published samples reached 44.65 mg/g. Whole powdered leaf is consumed. Caffeine is also present. |
| 2 |
Gyokuro green tea, shade-grown |
~31 |
3 g dry leaves |
Up to ~93 in leaves |
High-theanine Japanese green tea. Actual intake depends on extraction. A concentrated infusion study using 10 g leaves yielded approximately 168 mg in 60 mL. |
| 3 |
Matcha, other commercial grades |
2.5–10 |
2 g powder |
5–20 |
Measured values vary widely. Culinary grade and ordinary powdered green tea are not necessarily rich in L-theanine. |
| 4 |
Green tea leaves, including Sencha |
~6.6 average |
2 g leaves |
~13 in leaves |
One analytical survey measured 6.56 mg/g on average. Brewed intake is dependent on extraction. |
| 5 |
White tea leaves |
~6.3 average |
2 g leaves |
~13 in leaves |
One survey reported 6.26 mg/g. Individual cultivars and harvests can differ substantially. |
| 6 |
Oolong tea leaves |
~6.1 average |
2 g leaves |
~12 in leaves |
Measured mean 6.09 mg/g, with considerable variability. |
| 7 |
Black tea leaves |
~5.1 average |
2 g leaves |
~10 in leaves |
Mean dry-leaf content in one survey. Some brewed black teas deliver more L-theanine than green tea. |
| 8 |
Brewed black tea |
Not applicable |
200 mL |
~12–24 |
Measured means from different brewing studies. Values depend on tea selection, leaf quantity and steeping conditions. |
| 9 |
Brewed green tea |
Not applicable |
200 mL |
~8–13 |
Measured averages across different studies. Longer infusion can increase extracted L-theanine. |
| 10 |
Jasmine green tea, bottled |
Not applicable |
250 mL |
~9 |
Calculated from a measured average concentration of 36.6 mg/L in commercial ready-to-drink products. |
| 11 |
Green tea, bottled ready-to-drink |
Not applicable |
250 mL |
~9.5 |
Calculated from a measured average of 37.85 mg/L. Commercial formulations vary widely. |
| 12 |
Pu-erh tea |
Variable; sometimes very low |
200–250 mL |
Low or variable |
Processing and microbial fermentation may reduce theanine. Not a reliable high-theanine source. |
Notes: Values are approximate and based on published analytical measurements rather than standardized product specifications. Dry-leaf content represents the total present, not necessarily the amount extracted during brewing. Matcha is consumed as suspended whole-leaf powder, so its ingested L-theanine content is approximately the powder concentration multiplied by the serving mass. L-theanine supplements commonly provide 100–200 mg per capsule, generally without caffeine.
L-Theanine — A naturally occurring non-proteinogenic amino acid, chemically γ-glutamylethylamide, found predominantly in tea leaves (Camellia sinensis). It is classified as a nutraceutical and amino-acid derivative and is commonly abbreviated L-theanine or L-THE. It is structurally related to glutamate and can influence glutamatergic neurotransmission while also modulating stress, inflammatory, redox, and intracellular signaling pathways. L-Theanine is rapidly absorbed orally and crosses the blood-brain barrier. Its established human research base is primarily neurological and stress/sleep related; anticancer activity remains experimental.
Primary mechanisms (ranked):
- Suppression of growth-factor and prosurvival signaling, particularly EGFR/Met-AKT-NF-κB and ERK-NF-κB pathways, with reduced migration, invasion, and epithelial-mesenchymal transition in selected cancer models.
- Suppression of metastatic/EMT programs, including MMP9, Snail, N-cadherin, and vimentin with restoration of E-cadherin in prostate-cancer models.
- Promotion of apoptosis and suppression of proliferation in selected tumor models through pathways including Bax/Bcl-2, caspase activation, p53, and BMAL1.
- Modulation of STAT3/NOTCH1-BMAL1 signaling, cancer stemness, and drug-resistance pathways in cisplatin-resistant lung-cancer cells.
- Chemosensitization and altered chemotherapy handling in experimental models, including potentiation of cisplatin responses and historically reported modulation of glutamate-dependent drug transport.
- Redox and inflammatory modulation; antioxidant effects predominate in normal or stressed nonmalignant tissues, whereas tumor effects are context-dependent and are not best characterized as a generalized ROS-increasing mechanism.
- Glutamatergic signaling modulation and neuroprotection, including reduced excitotoxicity and secondary effects on GABAergic, dopaminergic, serotonergic, neurotrophic, and stress-response pathways.
Bioavailability / PK relevance: Oral L-theanine is rapidly absorbed. After 100 mg orally in healthy adults, plasma Cmax was approximately 24–27 µM with Tmax about 0.8 hour; exposure increased approximately dose-dependently from 50–200 mg. It is metabolized substantially to ethylamine and glutamate and is also excreted in urine. These pharmacokinetics are important when interpreting millimolar cell-culture experiments.
In-vitro vs systemic exposure relevance: Exposure is a major translational constraint. Several cytoprotective and mechanistic experiments use approximately 1–16 mM L-theanine, vastly above the tens-of-micromolar plasma concentrations produced by typical 100–200 mg oral doses. However, some cancer migration/invasion effects have been observed at approximately 32–125 µM, which is substantially closer to orally achievable systemic exposure. Anticancer effects demonstrated only at millimolar concentrations should therefore be considered low-translational-relevance unless supported by in-vivo pharmacology.
Clinical evidence status: Neurological/stress indications: small randomized controlled trials, with human evidence for stress reduction, attention/cognition, and selected sleep outcomes at approximately 200–400 mg/day. Cancer: preclinical only, including cell and animal models; no established anticancer efficacy in humans and no role as a standard cancer therapy. Chemosensitization remains experimental.
Cancer Mechanisms
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
EGFR / Met / AKT / NF-κB signaling |
↓ |
↔ |
R–G |
Growth, migration and survival ↓ |
One of the best-supported direct anticancer signaling axes. Reduced phosphorylation/expression of EGFR, Met, AKT and NF-κB has been demonstrated in cervical-cancer models. Related theanine derivatives are generally more potent than native L-theanine. |
| 2 |
ERK / NF-κB / MMP9 / Snail EMT axis |
↓ |
↔ |
R–G |
Migration, invasion and metastasis ↓ |
Prostate-cancer models show ERK/NF-κB suppression with MMP9, Snail, N-cadherin and vimentin ↓ and E-cadherin ↑. |
| 3 |
Apoptosis and mitochondrial survival signaling |
↑ apoptosis |
↓ apoptosis during oxidative injury |
G |
Tumor-cell death ↑ with normal-cell cytoprotection |
Context-selective effect. Cancer models report Bax/caspase activation and Bcl-2 suppression, whereas stressed normal cells can instead be protected from apoptosis. |
| 4 |
STAT3 / NOTCH1 / BMAL1 drug-resistance axis |
↓ STAT3/NOTCH1-associated stemness; BMAL1 modulation |
↔ |
G |
Cisplatin resistance and stemness ↓ |
Demonstrated primarily in cisplatin-resistant lung-cancer cells. Effect was much less evident in non-resistant cells and remains preclinical. |
| 5 |
BMAL1 / p53 signaling |
↑ BMAL1; ↑ p53 activity |
↔ |
G |
Proliferation and migration ↓; apoptosis ↑ |
Reported in melanoma. BMAL1 knockdown reduced the anticancer response, suggesting functional dependence on circadian-clock signaling. |
| 6 |
EMT and cell adhesion |
↓ EMT; ↑ E-cadherin |
↔ |
G |
Metastatic phenotype ↓ |
Particularly supported in prostate-cancer models and mechanistically overlaps with ERK/NF-κB/MMP9/Snail inhibition. |
| 7 |
Chemosensitization |
↑ (context-dependent) |
Potential toxicity protection (model-dependent) |
G |
Drug response ↑ |
Reported with cisplatin and in older experimental chemotherapy studies. This is not clinically established and should not be interpreted as evidence for routine combination use. |
| 8 |
ROS and antioxidant defense |
↔ (context-dependent) |
↓ ROS; ↑ GSH/SOD/GPx |
R–G |
Oxidative injury ↓ in normal cells |
L-Theanine is predominantly antioxidant in normal/stressed cells. A generalized ROS-increasing anticancer mechanism is not sufficiently established to classify ROS elevation as a core anticancer pathway. |
| 9 |
Inflammatory signaling |
↓ NF-κB and inflammatory signaling |
↓ inflammatory stress |
R–G |
Inflammation-associated signaling ↓ |
Potentially contributes to both tumor suppression and tissue protection; effects vary substantially by experimental model. |
| 10 |
Clinical Translation Constraint |
High-dose in-vitro effects may not be achievable systemically |
Human oral safety established substantially better than anticancer efficacy |
G |
Clinical anticancer relevance uncertain |
Typical 100 mg oral dosing produces plasma concentrations around 25 µM. Many mechanistic experiments use millimolar concentrations, although some migration effects occur in the tens-to-low-hundreds micromolar range. No human anticancer efficacy trial establishes therapeutic benefit. |
P: 0–30 min R: 30 min–3 hr G: >3 hr
Alzheimer’s disease / neurodegeneration relevance: L-Theanine has mechanistically plausible neuroprotective activity involving glutamatergic modulation, oxidative-stress reduction, anti-inflammatory signaling, neurotrophic support, and regulation of autophagy. Recent animal models report reduced amyloid-β burden, increased BDNF, activation of AMPK-associated autophagy, suppression of AKT/mTOR signaling, and improved memory. Human trials demonstrate effects on stress, attention, cognition, and sleep but do not establish prevention or treatment of Alzheimer’s disease.
Clinical translation: Evidence for Alzheimer’s disease itself remains preclinical. The human neurological evidence supports central nervous-system biological activity of orally administered L-theanine but should not be extrapolated to disease modification.
Neurodegeneration Mechanisms
| Rank |
Pathway / Axis |
Modulation |
Primary Effect |
Notes / Interpretation |
| 1 |
Glutamatergic excitotoxicity |
↓ |
Excitotoxic neuronal stress ↓ |
L-Theanine is structurally related to glutamate and can modulate glutamatergic neurotransmission; this is central to its neurobiological profile. |
| 2 |
AMPK / autophagy |
↑ AMPK; ↑ LC3-II; ↑ Beclin-1 |
Autophagic clearance and neuronal survival ↑ |
Supported in recent scopolamine-induced cognitive-dysfunction models. |
| 3 |
AKT / mTOR |
↓ p-AKT; ↓ p-mTOR |
Autophagy ↑ |
Closely linked to the AMPK/autophagy response in experimental neurodegeneration. |
| 4 |
BDNF neurotrophic signaling |
↑ |
Neuronal plasticity and survival ↑ |
Preclinical evidence; not yet demonstrated as an AD disease-modifying mechanism in humans. |
| 5 |
Amyloid-β burden |
↓ |
Amyloid pathology ↓ |
Observed in animal cognitive-impairment models; human AD evidence is lacking. |
| 6 |
Oxidative stress |
↓ ROS/MDA; ↑ GSH |
Neuronal oxidative injury ↓ |
Consistent with L-theanine's broader cytoprotective antioxidant effects. |
| 7 |
Neuroinflammation |
↓ |
Inflammatory neuronal injury ↓ |
TNF-α and related inflammatory signaling are reduced in several preclinical models. |
| 8 |
Clinical Translation Constraint |
Preclinical AD evidence |
Disease-modifying efficacy unproven |
Human studies support CNS activity, stress reduction, attention and selected cognitive outcomes but not Alzheimer’s treatment or prevention. |
|